Format

Send to

Choose Destination
Curr Opin Immunol. 2017 Aug;47:52-56. doi: 10.1016/j.coi.2017.06.010. Epub 2017 Jul 19.

CD8+ T cell programming by cytomegalovirus vectors: applications in prophylactic and therapeutic vaccination.

Author information

1
Vaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, OR, 97006, United States. Electronic address: fruehk@ohsu.edu.
2
Vaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, OR, 97006, United States. Electronic address: pickerl@ohsu.edu.

Abstract

Vectors based on cytomegalovirus (CMV) represent a novel vaccine platform that maintains high frequencies of non-exhausted effector memory T cells in both CMV sero-positive and sero-negative individuals. In non-human primate models, CMV vectored vaccines provide unprecedented protection against simian immunodeficiency virus (SIV). Moreover, CMV vectors can be genetically altered to program highly diverse CD8+ T cell responses that differ in their epitope targeting including conventional, MHC-I restricted CD8+ T cells as well as unconventional CD8+ T cells restricted by MHC class II or non-polymorphic MHC-E. By modifying cytomegaloviral determinants that control unconventional T cell priming it is possible to uniquely tailor the CD8+ T cell response for each individual disease target in order to maximize prophylactic or therapeutic protection.

PMID:
28734175
PMCID:
PMC5626601
DOI:
10.1016/j.coi.2017.06.010
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center